Brandl & Talos advises Series D investors on EUR 40 million financing round for Themis Bioscience

 

 

 

 

 

 

 

Themis Bioscience announced the closing of a EUR 40 million Series D financing round. Brandl & Talos advised the Series D investor consortium consisting of (1) Farallon Capital, (2) Adjuvant Capital, (3) Global Health Investment Fund, (4) Hadean Ventures, (5) Omnes Capital, (6) Ventech, (7) Wellington Partners Life Sciences und (8) aws Gründerfonds on one of the largest VC financing rounds in Austria to date in 2019. Another investor was MSD (tradename of Merck & Co., Inc., Kenilworth, N.J., USA). The transaction was led by Roman Rericha (partner at BTP) and Markus Arzt (attorney at BTP). Sabine Konrad (attorney at BTP) and Christina Bernhart (associate at BTP) were also members of the Brandl & Talos team.

We want to congratulate Themis on this remarkable financing round. The fact that we have succeeded in supporting a large number of highly renowned internationally investors in this extraordinary transaction shows our strong footprint in the venture capital sector. We wish Themis continued success,” comments Roman Rericha, Partner at Brandl & Talos Attorneys at Law.

MSD was represented by Baker McKenzie (Dr. Eva-Maria Ségur-Cabanac) and Themis Bioscience by Herbst Kinsky Rechtsanwälte (Dr. Florian Steinhart).

The proceeds from the financing round will be used to support the pivotal study for a vaccine against Chikungunya virus, a tropical disease transmitted by mosquitoes. An additional sum will also be allocated to the expansion of the clinical portfolio in infectious diseases and oncology.

Pressekontakt:
Andrea Blama
T +43 1 522 5700-82
communications@btp.at

Foto: Roman Rericha